AstraZeneca Stock - Analyst sentiment and long-term outlook in focus

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 17:54 CET. Details in the imprint.

AstraZeneca (GB0009895292) is one of the largest global pharmaceutical groups by market value and a core name in many healthcare portfolios. With no fresh company-specific headlines today, the focus turns to how the market values its long-term growth profile and business model.

How the market values AstraZeneca

AstraZeneca stock trades in New York under the ticker AZN via a Nasdaq listing, giving US investors direct access to the UK-based pharma group. The company’s primary listing, however, remains in London, where it is a heavyweight in the FTSE 100 index.

On secondary data platforms, recent quotes for AstraZeneca’s US-listed shares show a market capitalization in the area of $270 billion, putting the company among the most valuable global drugmakers. That scale reflects its broad portfolio and expectations for continued growth from key franchises.

Analyst sentiment and growth drivers

Consensus data compiled by market portals indicate that AstraZeneca stock carries a broad “Buy” rating from analysts, alongside an average 12-month price target materially above recent trading levels. This points to generally constructive long-term sentiment among covering banks.

Analysts typically highlight the company’s oncology pipeline, cardiovascular and renal treatments, and its ability to reinvest cash flows into late-stage trials as key drivers. They also watch patent cliffs and competition in core indications, factors that can temper otherwise robust growth expectations.

The product behind the stock

AstraZeneca generates revenue primarily from patented prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory, immunology, and rare diseases. Its oncology portfolio, including blockbuster therapies such as Tagrisso and Imfinzi, is widely seen as a central engine of earnings growth.

Where the stock trades today

The shares of AstraZeneca (GB0009895292) most actively trade on the London Stock Exchange under the ticker AZN, with parallel US trading via Nasdaq-listed shares, based on the latest available market data in GBP and USD.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.